Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study
Authors' conclusion
Gemigliptin had a comparable glucose-lowering efficacy without deleterious effects on cardiac functions or on biomarkers reflective of myocardial injury or heart failure during the 24-week observation period. However, larger, longer-term studies are needed to confirm these findings.
Study context
- Population
- Patients with T2D being treated with metforminextension up to 52 weeks
- Participants
- 60 patients
- Comparison
- Gemigliptin vs glimepiride added to metformin
- Primary endpoint
- Cardiac function (echocardiography) and cardiac biomarkers
- Follow-up
- 24 weeks
Primary result
As reported in the abstract
- Left ventricular end-diastolic volume decreased with gemigliptin but increased with glimepiride, borderline between-group difference
- Cardiac biomarkers did not change significantly in either group
Further findings
| Outcome | Gemigliptin | Glimepiride |
|---|---|---|
| HbA1c · baseline to 24 weeks | 6.8% ± 0.6% | 7.0% ± 0.7% |
| Baseline | 8.1% ± 0.6% | 8.1% ± 0.6% |
| HbA1c · up to 52 weeks | 7.3% ± 0.8% | 7.7% ± 1.3% |
HbA1c · baseline to 24 weeks
- Significant decrease in both groups, no between-group difference
HbA1c · up to 52 weeks
- Slight increase in both groups, no between-group difference
Metabolic and inflammatory markers, body composition
- Gemigliptin reduced insulin resistance, hs-CRP, LDL-C and blood pressure, and increased adiponectin vs glimepiride
- Gemigliptin induced favourable changes in body composition
Original publication
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study. Diabetes Obes Metab. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →